John Bassette – Health & Medicine

Amgen announces results of Stage 3 head-to-mind trial evaluating denosumab versus Zometa Amgen today announced detailed results from a Phase 3, head-to-head trial evaluating denosumab versus Zometa in the treatment of bone metastases in 2,046 individuals with advanced breast tumor that met its major and secondary endpoints and demonstrated superior efficacy in comparison to Zometa. These outcomes were presented today through the Presidential Session at the 2009 2009 ECCO 15 – ESMO 34 European Multidisciplinary Congress in Berlin, Germany .

60 years old

Jude Children's Research Medical center receives ANCC's Magnet designationNew study may lead to effective treatment to avoid common chemotherapy unwanted effects in malignancy patientsHigh dose flu vaccines significantly reduce hospitalization risk during influenza seasonAmplicare’s Mobile Companion may be used with the latest era smartphones, iPads and any notebook, PC or mini-Personal computer with Internet connectivity. It provides real-time access to update, view and create accounts, referral sources and detailed activity monitoring for account or advertising representatives.

Other Entries "specialist":

Random Entries